Literature DB >> 3170389

Reversal of activity of trimethoprim against gram-positive cocci by thymidine, thymine and 'folates'.

J M Hamilton-Miller1.   

Abstract

The reversal of the antibacterial activity of trimethoprim against different species of Gram-positive cocci (Staphylococcus aureus, Staph. epidermidis, Staph. saprophyticus, group B streptococci, Streptococcus faecalis and Str. faecium) by thymine, thymidine and various 'folates' (folate, folinate, dihydrofolate and tetrahydrofolate) was tested. Against group B streptococci and staphylococci only thymidine antagonized trimethoprim. However, for enterococci, thymine, thymidine, dihydrofolate, tetrahydrofolate and folinate all reversed the activity of trimethoprim, although by different amounts. Dihydrofolate was significantly more effective as a trimethoprim antagonist for Str. faecium than for Str. faecalis. While thymine and thymidine caused the MIC of trimethoprim against enterococci to increase more than 100-fold--thereby rendering them resistant--the 'folates' brought about much smaller increases in trimethoprim MIC, in the order of ten-fold only. Thus, even in the presence of 'folates' enterococci remain sensitive in vitro to trimethoprim.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170389     DOI: 10.1093/jac/22.1.35

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Antimicrobial susceptibility testing of aquatic bacteria: quality control disk diffusion ranges for Escherichia coli ATCC 25922 and Aeromonas salmonicida subsp. salmonicida ATCC 33658 at 22 and 28 degrees C.

Authors:  R A Miller; R D Walker; A Baya; K Clemens; M Coles; J P Hawke; B E Henricson; H M Hsu; J J Mathers; J L Oaks; M Papapetropoulou; R Reimschuessel
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.

Authors:  T M Coque; K V Singh; G M Weinstock; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Septicemia due to susceptible Enterococcus faecalis despite prophylaxis with trimethoprim-sulfamethoxazole.

Authors:  H A Elsner; W Krüger; R Laufs; D Mack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 3.267

5.  Antibiotic treatment of enterococcal infection.

Authors:  J M Hamilton-Miller
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 6.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

7.  Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli.

Authors:  T Tokunaga; K Oka; A Takemoto; Y Ohtsubo; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.

Authors:  Jee Hyun Park; William Craig; Karen Marchillo; David B Huang; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Lack of homology of enterococci which have high-level resistance to trimethoprim with the dfrA gene of Staphylococcus aureus.

Authors:  M Frosolono; S L Hodel-Christian; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 10.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.